MedTrace Logo

Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy.

NCT05029297 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2021-09-14

No results posted yet for this study

Summary

Clinical trial of "line extension" of drug ARAFARMADOL® 0.075% cream in a new formulation in topical solution applicable in roll-on and with the same therapeutic indications approved for the cream.

Conditions

  • Diabetic Neuropathy, Painful

Interventions

DRUG

Capsaicin

Sponsors & Collaborators

  • Fundación Teófilo Hernando, Spain

    collaborator OTHER

  • Arafarma Group, S.A.

    lead INDUSTRY

Principal Investigators

  • Dr. Raffaelle Carraro · Hospital Universitario La Princesa. Madrid. Investigator Site Coordinator.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-04
Primary Completion
2018-10-23
Completion
2018-10-23

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05029297 on ClinicalTrials.gov